deltaFLU / Vivaldi Biosci - LARVOL DELTA

Development of an intranasal, universal influenza vaccine in an EU-funded public-private partnership: the FLUniversal consortium. (PubMed, Front Immunol) - "An intranasal live attenuated vaccine, DeltaFLU, will be produced using an innovative platform; preclinical assessment in animal models and clinical studies using a controlled human infection model (CHIM) will be conducted for assessment of safety, immunogenicity and protective efficacy; and finally, comprehensive immunological analysis of blood and nasal mucosa will elucidate vaccine responses and potential new correlates of protection (CoPs)...Newly generated knowledge on mechanisms of protection, CoPs and new molecular analysis tools may significantly contribute to our knowledge on influenza infection and influenza vaccines. In conclusion, FLUniversal is an innovative and ambitious public-private partnership, aiming to present a new development pathway for influenza vaccines, and maximising impact by bringing together leading partners from academy and industry with a shared purpose of collaboration and innovation."

Journal • Licensing / partnership • Review • Infectious Disease • Influenza • Respiratory Diseases